trending Market Intelligence /marketintelligence/en/news-insights/trending/5zzr4jfes196bzqcz6sjfw2 content esgSubNav
In This List

Progenics Pharmaceuticals to raise $75M via common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Progenics Pharmaceuticals to raise $75M via common stock offering

Progenics Pharmaceuticals Inc. started an underwritten public offering of 9,090,909 common shares, priced $8.25 each.

The New York-based cancer drug developer expects to raise gross proceeds of about $75 million, which will go toward research and development as well as general corporate purposes.

Underwriters have a 30-day option to buy up to 1,363,636 additional common shares on the same terms and conditions.

The offering is expected to close on or around Aug. 10, subject to customary closing conditions.

Jefferies and Credit Suisse are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co. as lead manager. Needham & Co., BTIG and CIM Securities LLC are acting as co-managers.